Abstract:Proper evaluation of therapeutic responses in Chagas disease is hampered by the prolonged persistence of antibodies to Trypanosoma cruzi measured by conventional serological tests and by the lack of sensitivity of parasitological tests. Previous studies indicated that tGPI-mucins, an α-Gal (α- d -Gal p (1→3)-β- d -Gal p (1→4)- d -GlcNAc)-rich fraction obtained from T . cruzi trypomastigotes surface coat, elicit a strong and protective antibody response in infected individuals, which disappears soon after successful treatment. The cost and technical difficulties associated with tGPI-mucins preparation, however, preclude its routine implementation in clinical settings. We herein developed a neoglycoprotein consisting of a BSA scaffold decorated with several units of a synthetic α-Gal antigenic surrogate (α- d -Gal p (1→3)-β- d -Gal p (1→4)-β- d -Glc p ). Serological responses to this reagent, termed NGP-Tri, were monitored by means of an in-house enzyme-linked immunosorbent assay (α-Gal-ELISA) in a cohort of 82 T . cruzi -infected and Benznidazole- or Nifurtimox-treated children (3 days to 16 years-old). This cohort was split into 3 groups based on the age of patients at the time of treatment initiation: Group 1 comprised 24 babies (3 days to 5 months-old; median = 26 days-old), Group 2 comprised 31 children (7 months to 3 years-old; median = 1.0-year-old) and Group 3 comprised 26 patients (3 to 16 years-old; median = 8.4 years-old). A second, control cohort (Group 4) included 39 non-infected infants (3 days to 5 months-old; median = 31 days-old) born to T . cruzi -infected mothers. Despite its suboptimal seroprevalence (58.4%), α-Gal-ELISA yielded shorter median time values of negativization (23 months [IC 95% 7 to 36 months] vs 60 months [IC 95% 15 to 83 months]; p = 0.0016) and higher rate of patient negative seroconversion (89.2% vs 43.2%, p < 0.005) as compared to conventional serological methods. The same effect was verified for every Group, when analyzed separately. Most remarkably, 14 out of 24 (58.3%) patients from Group 3 achieved negative seroconversion for α-Gal-ELISA while none of them were able to negativize for conventional serology. Detailed analysis of patients showing unconventional serological responses suggested that, in addition to providing a novel tool to shorten follow-up periods after chemotherapy, the α-Gal-ELISA may assist in other diagnostic needs in pediatric Chagas disease. The tools evaluated here provide the cornerstone for the development of an efficacious, reliable, and straightforward post-therapeutic marker for pediatric Chagas disease. The limits of the current criterion for cure, i.e., negative seroconversion determined by conventional serology, and the lack of validated and sensitive markers for early assessment of response to trypanocidal drugs in Chagas disease stress the necessity of novel therapeutic response markers. Towards this goal, we herein developed by synthetic chemistry a neoglycoprotein bearing an α-Gal antigenic surrogate, termed NGP-Tri, and evaluated its performance in a large cohort of T . cruzi -infected and treated children. An α-Gal-ELISA built upon NGP-Tri showed a very good performance on the assessment of therapy efficacy, as it displayed significantly shorter median time value of negativization and higher rate of patient negative seroconversion as compared to conventional serology methods. These findings indicate that the tools developed here, as well as optimized versions derived from them, should have a positive impact on the clinical management of Chagas disease and the identification and/or clinical validation of novel drug candidates for the treatment of T . cruzi infections.

Trypanosoma cruzi antigen detection in blood to assess treatment efficacy and cure in mice models of Chagas disease

Aptamer Based, Non-PCR, Non-Serological Detection of Chagas Disease Biomarkers in Trypanosoma cruzi Infected Mice

Post-therapeutic cure criterion in chronic Chagas disease using Trypanosoma cruzi chimeric proteins

Characterization of Novel Trypanosoma cruzi-Specific Antigen with Potential Use in the Diagnosis of Chagas Disease

Apolipoprotein A1 and Fibronectin Fragments as Markers of Cure for the Chagas Disease

4-aminopyridyl-based lead compounds targeting CYP51 prevent spontaneous parasite relapse in a chronic model and improve cardiac pathology in an acute model of Trypanosoma cruzi infection

Evaluation of chimeric recombinant antigens for the serodiagnosis of Trypanosoma cruzi in dogs: a promising tool for Chagas disease surveillance

Lab on a chip (LOC) platform for drug screening against the intracellular forms of Trypanosoma cruzi

ECG Marker Evaluation for the Machine-Learning-Based Classification of Acute and Chronic Phases of Trypanosoma cruzi Infection in a Murine Model

Evaluation of the in vivo therapeutic properties of (-)-cubebin and (-)-hinokinin against Trypanosoma cruzi

Loop-Mediated Isothermal Amplification of Trypanosoma cruzi DNA for Point-of-Care Follow-Up of Anti-Parasitic Treatment of Chagas Disease

A Multi-Epitope Protein for High-Performance Serodiagnosis of Chronic Chagas Disease in ELISA and Lateral Flow Platforms

Animal models for exploring Chagas disease pathogenesis and supporting drug discovery

Repurposing strategies for Chagas disease therapy: the effect of imatinib and derivatives against Trypanosoma cruzi

An α-Gal antigenic surrogate as a biomarker of treatment evaluation in Trypanosoma cruzi -infected children. A retrospective cohort study

Impact of gastrointestinal inoculation and benznidazole treatment on infection by Trypanosoma cruzi (Y strain, DTU TcII) in Swiss mice

A Novel High-Content Screening-Based Method for Anti-Trypanosoma cruzi Drug Discovery Using Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes

Quantitative PCR as a marker for preemptive therapy and its role in therapeutic control in Trypanosoma cruzi /HIV coinfection

Near infrared spectroscopy accurately detects Trypanosoma cruzi non-destructively in midguts, rectum and excreta samples of Triatoma infestans

Dissimilar Trypanosoma cruzi genotype-specific serological profile assessed by Chagas-Flow ATE IgG1 upon benznidazole etiological treatment of chronic Chagas disease

High Throughput Screening for Anti–Trypanosoma cruzi Drug Discovery